GEOVAX LABS INC (GOVX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.21-3.15%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge GEOVAX LABS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.2
Annual ending 2026-12-31
Revenue	—	2.57M
EPS	—	-5.14
Annual ending 2027-12-31
Revenue	—	519.56M
EPS	—	-2.64

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
successful capital raising through private placements	The company is actively raising funds through private placements.	Under Pressure	failure to raise adequate capital or excessive dilution news	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
improving earnings per share trend	A primary condition in GEOVAX LABS INC's published investment case. The stated target is EPS loss narrows toward zero.	Improving	EPS loss widens or remains flat beyond FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
progress in M&A activity through definitive agreements	A supporting condition in GEOVAX LABS INC's published investment case. The stated target is complete accretive M&A deals to enhance operations.	Under Pressure	lack of meaningful M&A progress or failed deals	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 3 quarters. Management has engaged in material definitive agreements related to warrant exercise inducements as part of M&A activity. No disclosed revenue or operating income impact from these activities yet. The trajectory shows active pursuit of strategic agreements but limited financial delivery so far. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable	1 / 1
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 1
2026-08-01	Unavailable	Unavailable	1 / 1
2026-08-02	Unavailable	Unavailable	2 / 1
2026-08-03	Unavailable	Unavailable	2 / 1
2026-08-04	Unavailable	Unavailable	2 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	2 / 1
2026-08-07	Unavailable	Unavailable	1 / 1
2026-08-08	Unavailable	Unavailable	2 / 1
2026-08-09	Unavailable	Unavailable	2 / 1
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-12	Unavailable	Unavailable	2 / 1
2026-08-13	Unavailable	Unavailable	2 / 1
2026-08-14	Unavailable	Unavailable	1 / 1
2026-08-15	Unavailable	Unavailable	1 / 1
2026-08-16	Unavailable	Unavailable	1 / 1
2026-08-17	Unavailable	Unavailable	1 / 1
2026-08-18	Unavailable	Unavailable	1 / 1
2026-08-19	Unavailable	Unavailable	1 / 1
2026-08-20	Unavailable	Unavailable	2 / 1
2026-08-21	Unavailable	Unavailable	2 / 1
2026-08-22	Unavailable	Unavailable	2 / 1
2026-08-23	Unavailable	Unavailable	2 / 1
2026-08-24	Unavailable	Unavailable	2 / 1
2026-08-25	Unavailable	Unavailable	2 / 1
2026-08-26	Unavailable	Unavailable	2 / 1
2026-08-27	Unavailable	Unavailable	2 / 1
2026-08-28	Unavailable	Unavailable	2 / 1
2026-08-29	Unavailable	Unavailable	2 / 1
2026-08-30	Unavailable	Unavailable	2 / 1
2026-08-31	Unavailable	Unavailable	2 / 1
2026-09-01	Unavailable	Unavailable	2 / 1
2026-09-02	Unavailable	Unavailable	2 / 1
2026-09-03	Unavailable	Unavailable	2 / 1
2026-09-04	Unavailable	Unavailable	2 / 1
2026-09-05	Unavailable	Unavailable	2 / 1
2026-09-06	Unavailable	Unavailable	2 / 1
2026-09-07	Unavailable	Unavailable	2 / 1
2026-09-08	Unavailable	Unavailable	2 / 1
2026-09-09	Unavailable	Unavailable	2 / 1
2026-09-10	Unavailable	Unavailable	2 / 1
2026-09-11	Unavailable	Unavailable	2 / 1
2026-09-12	Unavailable	Unavailable	2 / 1
2026-09-13	Unavailable	Unavailable	2 / 1
2026-09-14	Unavailable	Unavailable	2 / 1
2026-09-15	Unavailable	Unavailable	2 / 1
2026-09-16	Unavailable	Unavailable	2 / 1
2026-09-17	Unavailable	Unavailable	2 / 1
2026-09-18	Unavailable	Unavailable	2 / 1
2026-09-19	Unavailable	Unavailable	2 / 1
2026-09-20	Unavailable	Unavailable	2 / 1
2026-09-21	Unavailable	Unavailable	2 / 1
2026-09-22	Unavailable	Unavailable	2 / 1
2026-09-23	Unavailable	Unavailable	2 / 1
2026-09-24	Unavailable	Unavailable	2 / 1
2026-09-25	Unavailable	Unavailable	2 / 1
2026-09-26	Unavailable	Unavailable	2 / 1
2026-09-27	Unavailable	Unavailable	2 / 1
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	2 / 1
2026-09-30	Unavailable	Unavailable	2 / 1
2026-10-01	Unavailable	Unavailable	2 / 1
2026-10-02	Unavailable	Unavailable	2 / 1
2026-10-03	Unavailable	Unavailable	2 / 1
2026-10-04	Unavailable	Unavailable	2 / 1
2026-10-05	Unavailable	Unavailable	2 / 1
2026-10-06	Unavailable	Unavailable	2 / 1
2026-10-07	Unavailable	Unavailable	2 / 1
2026-10-08	Unavailable	Unavailable	2 / 1
2026-10-09	Unavailable	Unavailable	2 / 1
2026-10-10	Unavailable	Unavailable	2 / 1
2026-10-11	Unavailable	Unavailable	2 / 1
2026-10-12	Unavailable	Unavailable	2 / 1
2026-10-13	Unavailable	Unavailable	2 / 1
2026-10-14	Unavailable	Unavailable	2 / 1
2026-10-15	Unavailable	Unavailable	2 / 1
2026-10-16	Unavailable	Unavailable	2 / 1
2026-10-17	Unavailable	Unavailable	2 / 1
2026-10-18	Unavailable	Unavailable	2 / 1
2026-10-19	Unavailable	Unavailable	2 / 1
2026-10-20	Unavailable	Unavailable	2 / 1
2026-10-21	Unavailable	Unavailable	2 / 1
2026-10-22	Unavailable	Unavailable	2 / 1
2026-10-23	Unavailable	Unavailable	2 / 1
2026-10-24	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	1
2026-06-01	2	1
2026-07-01	2	0
2026-08-01	2	0
2026-09-01	2	0
2026-10-01	2	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

successful capital raising through private placementsPublished status: Under Pressure
improving earnings per share trendDirect metric needs a verified mapping
progress in M&A activity through definitive agreementsPublished status: Under Pressure

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.9%Typical daily move · historical

Downside history

-98.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

GEOVAX LABS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

GOVX is a high-risk, loss-making clinical-stage biotech whose multi-year view depends on advancing its vaccine and cancer programs. The thesis is intact, but execution evidence is mixed and confidence in the assessment is medium.

What's priced into GEOVAX LABS INC

The snapshot describes GOVX as cheap versus peers, but confidence in that valuation comparison is low. It does not establish what the market already assumes about clinical progress, so the expectations gap is unclear.

What the fundamentals likely do

Near term, losses have remained around $4.4 million per quarter, while cash was stable at about $3.1 million from 2025-Q4 to 2026-Q2. Management continues to emphasize the GEO-MVA pivotal study and Gedeptin combinations, but disclosed clinical milestones remain limited; a guidance cut or earnings miss is a notable risk. The recent delisting notice and unregistered equity sale add uncertainty, while the sector backdrop has improved.

What GEOVAX LABS INC hinges on

The multi-year thesis hinges on initiating the planned GEO-MVA Phase 3 immunobridging study and showing meaningful progress in Gedeptin development. Near term, guidance and jobs data could weigh on the outlook, while stronger results and guidance from healthcare peers could support sector momentum.